NervGen Pharma Corp Dossier
Qualitative Analysis
Business overview
NervGen Pharma Corp. (NASDAQ: NGEN) is a clinical-stage biopharmaceutical company dedicated to developing first-in-class neuroreparative therapeutics designed to enable the nervous system to repair itself. The company's primary focus is on discovering, developing, and clinically validating therapies for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's lead therapeutic candidate is NVG-291, a subcutaneously administered neuroreparative peptide that targets the inhibitory chondroitin sulfate proteoglycan (CSPG) receptor, protein tyrosine phosphatase sigma (PTPσ). This mechanism aims to overcome the primary biological barriers to nervous system repair, promoting neuronal plasticity, sprouting, and remyelination. The company is also advancing a next-generation preclinical candidate, NVG-300, for indications such as ischemic stroke and spinal cord injury.
Research as of 24 Jul 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A randomized, double-blind, placebo-controlled Phase 3 trial co-developed with the FDA, designed to evaluate 12 weeks of daily subcutaneous treatment with NVG-291 in approximately 150 adults with chronic tetraplegia across up to 60 sites in the US and Canada.
Expected impact: Designed to serve as a registrational study to support a potential Biologics License Application (BLA) submission for NVG-291 in chronic tetraplegia.
Prioritizing and expanding the clinical development of NVG-291 into complementary neurotraumatic and neurologic indications, backed by established preclinical efficacy across more than 15 unique models.
Expected impact: Broadens the therapeutic pipeline and maximizes the commercial potential of the NVG-291 platform beyond spinal cord injury.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Utilizes Imeka's advanced neuroimaging technology (combining artificial intelligence and diffusion imaging) as a sensitive pharmacodynamic biomarker to map white matter integrity and detect precise neural changes in NVG-291 clinical trials.
Terms: Includes joint submissions for non-dilutive grants to support combining their respective technologies in preclinical and clinical studies.
Newton Tech performed independent, blinded biomechanical gait analyses of the Phase 1b/2a CONNECT SCI study using video-based motion capture and computational analysis to provide objective, quantitative measures of gait quality.
Terms: Terms of the service and analysis agreement were not publicly disclosed.